Daniel P. Walker

Discovery of<i>N</i>-[(3<i>R</i>)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-<i>c</i>]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia:  Synthesis and Structure−Activity Relationship

Donn G. Wishka, Daniel P. Walker, Karen M. Yates et al. · Journal of Medicinal Chemistry · 2006 · 190 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design

Seungil Han, Anil Mistry, Jeanne S. Chang et al. · Journal of Biological Chemistry · 2009 · 108 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Novel Riboswitch-Binding Flavin Analog That Protects Mice against Clostridium difficile Infection without Inhibiting Cecal Flora

Ken Blount, Cynthia M. Megyola, Mark S. Plummer et al. · Antimicrobial Agents and Chemotherapy · 2015 · 100 citations · Full text

Medicine, Microbiology, Pharmacology +13

Design, synthesis, structure–activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists

Daniel P. Walker, Donn G. Wishka, David W. Piotrowski et al. · Bioorganic & Medicinal Chemistry · 2006 · 94 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity

Daniel P. Walker, Michael P. Zawistoski, Molly A. McGlynn et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 88 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13